R&D Strategy
At Ferrer, we focus on identifying projects with differential value
To support Ferrer's purpose of using our business to fight for social justice, the R&D team aims to develop and deliver transformative therapeutic solutions for people living with severe and debilitating diseases.
Innovation is an inherent part of our pharmaceutical development, and we have always upheld our commitment in searching for and developing new treatment alternatives aimed at addressing unmet medical needs in order to improve the patients' quality of life and creating value for physicians, health systems and society at large.
We do this in two main areas:
Pulmonary vascular and interstitial lung diseases
Neurological disorders
We have brought together the talent, technical expertise, tools and scientific know-how to identify and deliver life changing therapies to patients with unmet needs. Our R&D focus is to bring innovative drug delivery approaches to enhance medicines to treat disease condition, progression and symptoms. We also utilize state of the art digital technology to develop products and services which, together with our drug therapies, offer new approaches for non-invasive therapeutic support for patients.
Our dynamic R&D strategy improves our understanding of the diseases which drives development of potential new therapies. Development is guided by patient journeys which reflect their daily life, enabling us to make smart, well-integrated choices for rapid adoption to new challenges and opportunities.
The patients and their needs are always at the forefront of our development strategy as we research, create, innovate, and develop therapeutic products. We work for patients to provide life-altering therapies-products that revolutionize the effectiveness of their medicine and improve the quality of their lives.
Pipeline
Our innovative approach has resulted in multiple product candidates under development that have the potential to improve the quality of life for patients. Our researchers continually evaluate opportunities to develop and deliver differential and meaningful solutions.
We are driven to create impactful new drug products for the chronic or acute treatment of debilitating symptoms and conditions.
Our current pipeline is patient-centric and spans across our therapeutic focus areas: pulmonary vascular and interstitial lung diseases and neurological disorders.
In addition, we are developing products that have the potential to respond to the unmet needs of patients with cyclic vomiting syndrome (CVS) and diabetic retinopathy. Those programs are available for collaboration in some geographies.
| DEVELOPMENT PROGRAMS | PRECLINICAL | PHASE I | PHASE II | PHASE III | REGISTRY | MARKET |
|---|---|---|---|---|---|---|
| NEUROLOGICAL DISORDERS | ||||||
| FNP 253* – Huntington Disease (HD) | ||||||
| FNP 254* – Amyotrophic Lateral Sclerosis (ALS) | ||||||
| FNP 223 – Progressive Supranuclear Palsy (PSP) | ||||||
| FNP 002** – Rapid Epileptic Seizure Termination (REST) | ||||||
| PULMONARY VASCULAR & INTERSTITIAL LUNG DISEASES | ||||||
| Tyvaso®***$ – Pulmonary Hypertension – Interstitial Lung Disease (PH-ILD) | ||||||
| Tyvaso®*** – Idiopathic Pulmonary Fibrosis (IPF) | ||||||
| Tyvaso®*** – Progressive Pulmonary Fibrosis (PPF) | ||||||
| FNP 321~ – Medical Device for Pulmonary Arterial Hypertension (PAH) | ||||||
| FNP 221 – Medical Device for Pulmonary Hypertension – Interstitial Lung Desease (PH-ILD) |
Other formulation capability
Our R&D scientists have expertise in a range of formulations, including extended release, oral dosage forms, oral suspensions, semi-solids and injectable depots (microparticles for prolonged release). Ferrer utilizes these diverse technologies to improve existing drugs, creating more effective and/or convenient therapies for patients in our therapeutic areas of focus.